JAFL
IBRX icon

Jay A. Fishman Ltd’s ImmunityBio IBRX Stock Holding History

Jay A. Fishman Ltd’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-145,600
Closed -$731K – 92
2023
Q4 		$731K Sell
145,600
-16,400
-10% -$51.5K 0.08% 54
2023
Q3 		$274K Hold
162,000
– – 0.03% 83
2023
Q2 		$450K Buy
162,000
+50,000
+45% +$141K 0.05% 71
2023
Q1 		$204K Buy
112,000
+89,000
+387% +$277K 0.03% 89
2022
Q4 		$117K Buy
23,000
+13,000
+130% +$71.4K 0.02% 95
2022
Q3 		$49.7K Buy
+10,000
New +$45.6K 0.01% 90

Other funds holding IBRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jay A. Fishman Ltd's IBRX Position: Q1 2024 in Review

Jay A. Fishman Ltd sold out of ImmunityBio (IBRX) in Q1 2024, closing a stake of 145,600 shares — an estimated $731K sold.

Jay A. Fishman Ltd first reported a position in IBRX in Q3 2022 and held it in 6 quarters. The position peaked at $731K in Q4 2023. 165 funds tracked by Wall St. Rank hold IBRX as of Q1 2024.

  • Jay A. Fishman Ltd reported no remaining ImmunityBio position as of Q1 2024 after selling out during the quarter.
  • Jay A. Fishman Ltd sold 145,600 ImmunityBio shares in Q1 2024, an estimated $731K.
  • Jay A. Fishman Ltd first reported a position in ImmunityBio in Q3 2022 and held it in 6 quarters.
  • Jay A. Fishman Ltd's ImmunityBio position peaked at $731K in Q4 2023.
  • 165 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2024.

Based on Jay A. Fishman Ltd's 13F filing for Q1 2024, filed 23 Apr 2024.